Guggenheim Has Lowered Expectations for Valneva (NASDAQ:VALN) Stock Price

Valneva (NASDAQ:VALN) had its target price dropped by research analysts at Guggenheim from $17.00 to $15.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective indicates a potential upside of 112.16% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Valneva in a research report on Friday, March 21st.

Valneva Price Performance

NASDAQ VALN opened at $7.07 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The stock has a market cap of $574.52 million, a price-to-earnings ratio of -54.38 and a beta of 1.93. The business has a 50 day simple moving average of $6.45 and a 200 day simple moving average of $5.59. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50.

Valneva (NASDAQ:VALN) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The company had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. Analysts anticipate that Valneva will post 0.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA purchased a new position in shares of Valneva SE (NASDAQ:VALN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,244 shares of the company’s stock, valued at approximately $84,000. 11.39% of the stock is owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.